Author

R. Tesch

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Approach:deep learning· 2 Organism:human· 2 Assay:proteomics· 2 Approach:statistical model· 1

Frequent Co-Authors

L. M. Berger· 4 shared S. Knapp· 4 shared T. Hanke· 4 shared A. C. Joerger· 3 shared A. Poso· 3 shared I. Abdi· 3 shared M. Rak· 3 shared T. Kronenberger· 3 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

L. M. Berger

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Development of selective pyridopyrimidin-7(8H)-one-based Mammalian STE20-like (MST3/4) kinase inhibitors

M. Rak, A. Menge, R. Tesch, L. M. Berger, D.-I. Balourdas, E. Shevchenko, A. Kraemer, L. Elson, B.-T. Berger, I. Abdi, L. M. Wahl, A. Poso, A. Kaiser, T. Hanke, T. Kronenberger, , S. Knapp

This study develops selective MST3/4 kinase inhibitors and demonstrates their distinct cellular effects compared to MST1/2 inhibition.

bioRxiv · Nov 24, 2023Biochemistry

Shifting the selectivity of pyridopyrimidin-7(8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily

M. Rak, R. Tesch, L. M. Berger, E. Shevchenko, M. Raab, A. Tjaden, R. Zhubi, D.-I. Balourdas, A. C. Joerger, A. Poso, A. Kraemer, L. Elson, A. Lucic, T. Kronenberger, T. Hanke, , S. Knapp

This paper develops a selective SIK kinase inhibitor, MR22, by optimizing a pyrido[2,3-d]pyrimidin-7(8H)-one scaffold to eliminate PAK activity, demonstrating its efficacy in ovarian cancer cells.

European Journal of Medicinal Chemistry · Jun 1, 2023Peer-reviewedBiochemistry

Structure-based design of selective salt-inducible kinase (SIK) inhibitors

R. Tesch, M. Rak, M. Raab, L. M. Berger, T. Kronenberger, A. C. Joerger, B. T. Berger, I. Abdi, T. Hanke, A. Poso, K. Strebhardt, M. Sanhaji, S. Knapp

This study designs a selective SIK inhibitor, MRIA9, based on a PAK inhibitor, showing its dual activity and potential for combination therapy in ovarian cancer.

bioRxiv · Apr 8, 2021 · PreprintBiochemistry

A Highly Selective Chemical Probe for Activin Receptor-like Kinases ALK4 and ALK5

T. Hanke, J. F. Wong, B.-T. Berger, I. Abdi, L. M. Berger, R. Tesch, C. Tredup, A. N. Bullock, S. Mueller, S. Knapp

The paper develops a selective chemical probe, TP-008, for ALK4 and ALK5 kinases and provides a negative control, enabling mechanistic studies of their signaling pathway and disease roles.

bioRxiv · Jan 23, 2020Biochemistry